Valuation : Fortress Biotech, Inc.

Market Cap 85.71M 73.85M 69.93M 63.38M 119M 8.19B 120M 830M 319M 4.17B 322M 315M 13.16B P/E 2026 *
1.01x
P/E 2027 * -2.57x
Enterprise Value 85.71M 73.85M 69.93M 63.38M 119M 8.19B 120M 830M 319M 4.17B 322M 315M 13.16B EV / Sales 2026 *
1.09x
EV / Sales 2027 * 0.76x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.97%
1 week-6.62%
Current month-7.13%
1 month-2.68%
3 months-7.97%
6 months-21.12%
Current year-30.60%
1 week 2.53
Extreme 2.53
2.75
1 month 2.53
Extreme 2.53
3.06
Current year 2.18
Extreme 2.18
4.53
1 year 2.18
Extreme 2.18
4.53
3 years 1.24
Extreme 1.24
6.15
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap. Importance
1/4/26 Free

Chief Financial Officer

2,967 0.0096%
18/3/26 Free

Chief Executive Officer

475,424 1.5318%
18/3/26 Free

Director

475,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%-6.62%-33.68%-53.82% 85.71M
-1.35%-5.29%+37.97%-5.95% 79.21B
-1.42%-4.79%-20.78%-38.31% 58.22B
+7.37%+2.06%+485.07%+40.41% 54.54B
-0.56%-4.20%-11.00%+27.11% 48.89B
+1.93%-2.37%-2.00%+149.45% 44.72B
+1.61%-0.59%+47.49%-15.22% 31.83B
-0.43%-3.09%+42.54%+90.70% 24.99B
-0.85%-8.82%-6.07%+164.64% 20.95B
-0.09%-3.61%+63.58%+97.66% 15.8B
Average +0.54%-5.30%+60.31%+45.67% 37.92B
Weighted average by Cap. +0.78%-5.38%+81.95%+37.66%

Financials

2026 *2027 *
Net sales 78.79M 67.89M 64.28M 58.27M 109M 7.53B 110M 763M 294M 3.83B 296M 289M 12.1B 113M 97.58M 92.39M 83.74M 157M 10.82B 158M 1.1B 422M 5.5B 425M 416M 17.39B
Net income 88.25M 76.03M 71.99M 65.26M 122M 8.43B 123M 855M 329M 4.29B 331M 324M 13.55B -37.81M -32.58M -30.85M -27.96M -52.46M -3.61B -52.72M -366M -141M -1.84B -142M -139M -5.81B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
12/09/26 US$2.540 -1.17% 154,069
10/09/26 US$2.570 -2.28% 315,547
09/09/26 US$2.630 -2.95% 280,401
08/09/26 US$2.710 -0.37% 263,047
04/09/26 US$2.720 +0.37% 168,144
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.570USD
Average target price
11.00USD
Spread / Average Target
+328.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!